Long non-coding RNA RP11-70C1.3 confers chemoresistance of breast cancer cells through miR-6736-3p/NRP-1 axis

Chemoresistance remains a major obstacle for improving the clinical outcome of patients with breast cancer. Recently, long non-coding RNAs (lncRNAs) have been implicated in breast cancer chemoresistance. However, the function and underlying mechanism are still largely unknown. Using lncRNA microarray, we identified 122 upregulated and 475 downregulated lncRNAs that might be related to the breast cancer chemoresistance. Among them, RP11-70C1.3 was one of the most highly expressed lncRNAs. In breast cancer patients, high RP11-70C1.3 expression predicted poor prognosis. Knockdown of RP11-70C1.3 inhibited the multidrug resistance of breast cancer cells in vitro and in vivo. Further investigations revealed that RP11-70C1.3 functioned as a competing endogenous RNA for miR-6736-3p to increase NRP-1 expression. Notably, the rescue experiments showed that both miR-6736-3p inhibitor and NRP-1 overexpression could partly reverse the suppressive influence of RP11-70C1.3 knockdown on breast cancer chemoresistance. In conclusion, our study indicated that lncRNA RP11-70C1.3 regulated NRP-1 expression by sponging miR-6736-3p to confer chemoresistance of breast cancer cells. RP11-70C1.3 might be a potential therapeutic target to enhance the clinical efficacy of chemotherapy in breast cancer.

Automated summary

This study investigates the role of long non-coding RNA RP11-70C1.3 in breast cancer chemoresistance. It is found that RP11-70C1.3 regulates NRP-1 expression by sponging miR-6736-3p, thus conferring chemoresistance in breast cancer cells. RP11-70C1.3 may serve as a potential therapeutic target to improve the clinical efficacy of chemotherapy in breast cancer.